North Bergen, New Jersey--(Newsfile Corp. - January 7, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), announces that the Letter of Intent between the Company and Revive Regenerative, Inc., dated September 12, 2025, (the "LOI") has expired and it no longer in effect.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/279422_3bd62a33d4b12bbb_001full.jpg
The LOI contained a proposed closing date of October 31, 2025, unless extension was provided in writing by the parties. No such extension was ever provided by either party; therefore, the current Letter of Intent is null and void. There are significant negotiations continuing on newly restructured partnership between the companies, in addition, the Company (Apollo) is actively seeking other opportunities and options that have been presented to it, in addition to the partnership with Revive Regenerative.
Additionally, the Company is aware of the Legal Issues with respect to Jay Lucas and Lucas Brand Equity. Mr. Lucas was a member of the Board of Directors of the Company for all of 2024. He was formally removed from the Board in March 2025, upon mutually agreeable terms, for business reasons. He has not had any contact or relationship with the Company since March 2025. Lucas Brand Equity had previously contracted with the Company to raise capital for the Company, but only a very minimal amount of money was raised, which is properly noted on the Company's Financials.
Lucas Brand Equity and Jay Lucas are in no way legally contractually or affiliated with LB Equity Advisors Inc. LB Equity Advisors, Inc., has no connection of any kind with Mr. Lucas.
The Company and its legal counsel are investigating any relationship with Mr. Lucas to ensure that the Company was in full compliance in the past with all laws regarding its affiliation with Mr. Lucas.
James W. Zimbler, President and CEO, stated, "The Letter of Intent with Revive Regenerative, Inc., has ended, and negotiations on a new partnership continue and we are hopeful of a continuing relationship and a new partnership going forward. In addition, we are exploring other potential business opportunities. We are aware of the unfortunate legal problems of Mr. Lucas and want to emphasize that he has no connection with the Company at all since March of 2025. We wish him well. The Company will provide updates on the new developments in the days ahead."
The Company uses the following handle on X at @ApolloBioKOAN to communicate with its shareholders.
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420
X at @ApolloBioKOAN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279422
Source: Apollo Biowellness, Inc.
